Selected articles
Articles for label Brančíková Dagmar are displayed.. Show all articles
First experience with abemaciclib in real clinical practice – case report
03/2020 MUDr. Dagmar Brančíková, Ph.D.
We describe the case of a 41-year-old patient with breast cancer, where there was primarily surgical liver dissemination and then bone dissemination. The immunoprofile of the hormone-dependent primary tumor was different from the metastasis, which was triplet negative. The patient was treated systemically with hormone therapy with tamoxifen and a combination of cyclin-dependent kinase inhibitors and letrozole. Cyclin-dependent kinase inhibitors were varied according to the adverse event profile. The best tolerated treatment was the combination of abemaciclib with letrozole. Treatment with the combination with denosumab was effective, we achieved partial remission of lung metastases and stabilization of bone.
ENTIRE ARTICLE
We describe the case of a 41-year-old patient with breast cancer, where there was primarily surgical liver dissemination and then bone dissemination. The immunoprofile of the hormone-dependent primary tumor was different from the metastasis, which was triplet negative. The patient was treated systemically with hormone therapy with tamoxifen and a combination of cyclin-dependent kinase inhibitors and letrozole. Cyclin-dependent kinase inhibitors were varied according to the adverse event profile. The best tolerated treatment was the combination of abemaciclib with letrozole. Treatment with the combination with denosumab was effective, we achieved partial remission of lung metastases and stabilization of bone.
Treatment of metastatic HER2 positive breast cancer in young patient with very advanced disease – case report
04/2019 MUDr. Markéta Protivánková; MUDr. Dagmar Brančíková, Ph.D.; MUDr. Jiří Vašina
Although the percentage of patients diagnosed in the early stage of the disease is increasing after the introduction of breast cancer screening, a large group of patients still have metastatic breast cancer. Advanced HER2 positive breast cancer has been therapeutically difficult to treat with adverse prognosis until the introduction of targeted anti-HER2 therapy, and its therapy has been complicated by a number of possible side effects and considerable toxicity. Our case report describes a case of a 42-year-old patient who had HER2 positive breast cancer diagnosed at a very advanced stage of the disease. After the use of dual-block treatment with concomitant administration of trastuzumab and pertuzumab, a high-quality and long-term response of the disease was achieved in which the quality of life of the patient significantly increased. At the same time, this treatment was very well tolerated.
ENTIRE ARTICLE
Although the percentage of patients diagnosed in the early stage of the disease is increasing after the introduction of breast cancer screening, a large group of patients still have metastatic breast cancer. Advanced HER2 positive breast cancer has been therapeutically difficult to treat with adverse prognosis until the introduction of targeted anti-HER2 therapy, and its therapy has been complicated by a number of possible side effects and considerable toxicity. Our case report describes a case of a 42-year-old patient who had HER2 positive breast cancer diagnosed at a very advanced stage of the disease. After the use of dual-block treatment with concomitant administration of trastuzumab and pertuzumab, a high-quality and long-term response of the disease was achieved in which the quality of life of the patient significantly increased. At the same time, this treatment was very well tolerated.
Breast cancer immunotherapy – a promising way?
04/2019 MUDr. Dagmar Brančíková, Ph.D.; MUDr. Markéta Protivánková
Immunotherapy is an emerging new modality in the treatment of many tumors. In the treatment of breast carcinomas, there is already the first experience with this treatment, which gradually defines the subgroups of patients and stages of breast malignancies that receive the highest profits from immunotherapy alone or in combinations with chemotherapy and target therapy. We present a review of the literature on clinical (age, weight, gender) and laboratory parameters that predict the response to immunotherapy and an overview of suitable combinations with chemotherapy or targeted agents in the treatment of metastatic breast cancer. Monotherapy checkpoint inhibitors do not yet appear to be effective but combinations atezolizumab or pembrolizumab with nab-paclitaxel and eribulin mesylate in neoadjuvant and in the first line of palliation are very promising in the treatment of triple-negative breast cancer locally advanced. So far, in the treatment of HER (epidermal growth factor receptor) positive tumors and ER (estrogen receptor) positive, a subset of patients with significant immunotherapy benefit cannot be unequivocally established.
ENTIRE ARTICLE
Immunotherapy is an emerging new modality in the treatment of many tumors. In the treatment of breast carcinomas, there is already the first experience with this treatment, which gradually defines the subgroups of patients and stages of breast malignancies that receive the highest profits from immunotherapy alone or in combinations with chemotherapy and target therapy. We present a review of the literature on clinical (age, weight, gender) and laboratory parameters that predict the response to immunotherapy and an overview of suitable combinations with chemotherapy or targeted agents in the treatment of metastatic breast cancer. Monotherapy checkpoint inhibitors do not yet appear to be effective but combinations atezolizumab or pembrolizumab with nab-paclitaxel and eribulin mesylate in neoadjuvant and in the first line of palliation are very promising in the treatment of triple-negative breast cancer locally advanced. So far, in the treatment of HER (epidermal growth factor receptor) positive tumors and ER (estrogen receptor) positive, a subset of patients with significant immunotherapy benefit cannot be unequivocally established.
Sunitinib in the treatment of neuroendocrine tumors of the gastrointestinal tract – case study
01/2019 MUDr. Dagmar Brančíková, Ph.D.
Pheochromocytomas are rare tumors. Bilateral adrenal medullary pheochromocytomas are components of MEN- Ila and MEN Ilb (multiple endocrine neoplasia). Patient 55 years old with inoperable pheochromocytoma, with liver and abdomen cavity metastases in the time of diagnosis had high levels of adrenalin, noradrenalin and dopamin. Patient was treated by TACE, lanreotide and target therapy. The patient lives 5 years after the diagnosis of disease dissemination and 18 years after the first manifestation, with very good effect and quality of life. The case demonstrates the good effect of hormonal and anti-cancer treatment.
ENTIRE ARTICLE
Pheochromocytomas are rare tumors. Bilateral adrenal medullary pheochromocytomas are components of MEN- Ila and MEN Ilb (multiple endocrine neoplasia). Patient 55 years old with inoperable pheochromocytoma, with liver and abdomen cavity metastases in the time of diagnosis had high levels of adrenalin, noradrenalin and dopamin. Patient was treated by TACE, lanreotide and target therapy. The patient lives 5 years after the diagnosis of disease dissemination and 18 years after the first manifestation, with very good effect and quality of life. The case demonstrates the good effect of hormonal and anti-cancer treatment.
New recommendations for neoadjuvant treatment of HER2‑positive breast cancer patients
04/2017 MUDr. Dagmar Brančíková, Ph.D., MUDr. Markéta Protivánková
Treatment of locally advanced breast cancer with HER2/neu amplification is systemic and consists of chemotherapy and receptor blockade. The neoadjuvant procedure is designed to rapidly reduce tumor mass and operability, despite the misgivings of several studies, the complete remission remains pathological (pCR) is a reliable substitute Time to progression or overall survival. In this paper we present a summary of some experience with chemotherapy regimens and HER2/neu blockers and their potential combinations. The most promising 3-year data from trial NeoSphere show a promising trend to improve progression free survival for the combination of docetaxel/trastuzumab/pertuzumab that increased pCR from 29% to 46%. In all neoadjuvant studies, the group of patients with a hormone-positive disease had less benefit from anti-HER2 blockade and chemotherapy, but this procedure has yet to be verified as the best.
ENTIRE ARTICLE
Treatment of locally advanced breast cancer with HER2/neu amplification is systemic and consists of chemotherapy and receptor blockade. The neoadjuvant procedure is designed to rapidly reduce tumor mass and operability, despite the misgivings of several studies, the complete remission remains pathological (pCR) is a reliable substitute Time to progression or overall survival. In this paper we present a summary of some experience with chemotherapy regimens and HER2/neu blockers and their potential combinations. The most promising 3-year data from trial NeoSphere show a promising trend to improve progression free survival for the combination of docetaxel/trastuzumab/pertuzumab that increased pCR from 29% to 46%. In all neoadjuvant studies, the group of patients with a hormone-positive disease had less benefit from anti-HER2 blockade and chemotherapy, but this procedure has yet to be verified as the best.